{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:56:32Z","timestamp":1775836592362,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T00:00:00Z","timestamp":1537574400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10067-018-4306-9","type":"journal-article","created":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T00:55:26Z","timestamp":1537577726000},"page":"3159-3165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["International position paper on the appropriate use of uricosurics with the introduction of lesinurad"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3026-3154","authenticated-orcid":false,"given":"Tim L.","family":"Jansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Perez-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Kathrin","family":"Tausche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Richette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,22]]},"reference":[{"key":"4306_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jare.2017.04.008","volume":"8","author":"G Ragab","year":"2017","unstructured":"Ragab G, Elshahaly M, Bardin T (2017) Gout: an old disease in new perspective. A review. J Adv Res 8:495\u2013511","journal-title":"J Adv Res"},{"issue":"1","key":"4306_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2016","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, Coyfish M, Guillo S, Jansen TL, Janssens H, Liote F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2016) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2016-209707","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"suppl_1","key":"4306_CR3","doi-asserted-by":"publisher","first-page":"i51","DOI":"10.1093\/rheumatology\/kex421","volume":"57","author":"A Abhishek","year":"2018","unstructured":"Abhishek A, Doherty M (2018) Education and non-pharmacological approaches for gout. Rheumatology (Oxford) 57(suppl_1):i51\u2013i58. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kex421","journal-title":"Rheumatology (Oxford)"},{"key":"4306_CR4","first-page":"2014","volume":"18","author":"J Miner","year":"2016","unstructured":"Miner J, Tan Ph K, Hyndman D et al (2016) Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther 18:2014\u20132023","journal-title":"Arthritis Res Ther"},{"key":"4306_CR5","doi-asserted-by":"publisher","unstructured":"Zimmerman HJ, Lewis JH, Ishak KG, Maddrey WC. (1984) Ticrynafen-associated hepatic injury: analysis of 340 cases. Hepatology 4: DOI \n                    https:\/\/doi.org\/10.1002\/hep\/1840040223","DOI":"10.1002\/hep\/1840040223"},{"key":"4306_CR6","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s10067-016-3273-2","volume":"35","author":"P Dua","year":"2016","unstructured":"Dua P, Gurrell R, Kirby S, Sudworth M, Loudon PT (2016) Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase\/URAT1 dual inhibitor PF-06743649. Clin Rheumatol 35:2045\u20132051","journal-title":"Clin Rheumatol"},{"key":"4306_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","volume":"31","author":"MH Lee","year":"2008","unstructured":"Lee MH, Graham GG, Williams KM, Day RO (2008) A benefit-risk assessment of benzbromarone in the treatment of gout. Was withdrawal from the market in the best interest of patients? Drug Saf 31:643\u2013665","journal-title":"Drug Saf"},{"key":"4306_CR8","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","volume":"56","author":"AK Tausche","year":"2017","unstructured":"Tausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, Adler S, Bhakta N, Storgard C, Baumgartner S, Saag K (2017) Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extensions study. Rheumatology 56:2170\u20132178. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kex350","journal-title":"Rheumatology"},{"key":"4306_CR9","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/art.40159","volume":"69","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, Adler S, Fung M, Storgard C, Baumgartner S, Perez-Ruiz F (2017) Lesinurad, a selective uric acid reabsorption inhibitor, in comparison with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis Rheum 69:1903\u20131913","journal-title":"Arthritis Rheum"},{"key":"4306_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/art.39840","volume":"69","author":"KG Saag","year":"2017","unstructured":"Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, Becker MA (2017) Lesinurad combined with allopurinol: a randomized, double blind, placebo controlled study in gout patients with an inadequate response to standard-of-care allopurinol. Arthritis Rheum 69:203\u2013212","journal-title":"Arthritis Rheum"},{"key":"4306_CR11","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","volume":"76","author":"T Bardin","year":"2017","unstructured":"Bardin T, Keenan RT, Khanna PP, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, So A (2017) Lesinsurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard-of-care (the multinational CLEAR 2 study). Ann Rheum Dis 76:811\u2013820","journal-title":"Ann Rheum Dis"},{"key":"4306_CR12","doi-asserted-by":"publisher","unstructured":"Bardin Th, Karra RG, So A, Tausche A-K, Wild I, Hagedorn H, Kandaswamy P, Perez-Ruiz F. (2018) Lesinurad adjunctive therapy with allopurinol in patients not responding to allopurinol monotherapy: pooled post-hoc safety and efficacy analysis in a patient subgroup using concomitant diuretics at baseline Ann Rheum Dis 77: DOI: \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2018-eular.2812","DOI":"10.1136\/annrheumdis-2018-eular.2812"},{"issue":"4","key":"4306_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cpdd.323","volume":"6","author":"Z Shen","year":"2017","unstructured":"Shen Z, Tieu K, Wilson D, Bucci G, Gillen M, Lee C, Kerr B (2017) Evaluation of pharmacokinetic interactions between Lesinurad, a new selective urate reabsorption inhibitor, and commonly used drugs for gout. Clin Pharmacol in Drug Development 6(4):377\u2013387. \n                    https:\/\/doi.org\/10.1002\/cpdd.323","journal-title":"Clin Pharmacol in Drug Development"},{"key":"4306_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cpdd.323","volume":"6","author":"Z Shen","year":"2017","unstructured":"Shen Z, Tieu K, Wilson D, Bucci G, Gillen M, Lee C, Keer B (2017) Evaluation of pharmacokinetic interactions between lesinurad, a new selective urate reabsorption inhibitor, and commonly used drugs for gout treatment. Clin Pharmacol Drug Dev 6:377\u2013387. \n                    https:\/\/doi.org\/10.1002\/cpdd.323","journal-title":"Clin Pharmacol Drug Dev"},{"key":"4306_CR15","doi-asserted-by":"publisher","unstructured":"Van Booven D, Marsh S, McLeod H, Whirl Carrillod M, Sangkuhld K, Kleind TE, Altman RB (2010) Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics 20(4):277\u2013281. \n                    https:\/\/doi.org\/10.1097\/FPC.0b013e3283349e84","DOI":"10.1097\/FPC.0b013e3283349e84"},{"issue":"1","key":"4306_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/ard.2007.083071","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders MK, Van Roon EN, Jansen TLTA et al (2009) Efficacy and tolerability of urate lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 68(1):51\u201356. \n                    https:\/\/doi.org\/10.1136\/ard.2007.083071","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4306_CR17","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1136\/ard.2008.091462","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, Brouwers JR (2009) A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg\/day versus benzbromarone 100-200 mg\/day in patients with gout. Ann Rheum Dis 68(6):892\u2013897. \n                    https:\/\/doi.org\/10.1136\/ard.2008.091462","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4306-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4306-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4306-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T19:13:17Z","timestamp":1569093197000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4306-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,22]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4306"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4306-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,22]]},"assertion":[{"value":"13 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TJ: Research support from Ardea\/Olatec; Lecture fees from Grunenthal; Consultancy fees from Abbvie\/Astra-Zeneca\/Celgene\/Novartis; FPR: Consultancy fee for AstraZeneca, Horizon, Gr\u00fcnenthal, Menarini; speaker for Gr\u00fcnenthal and Menarini; investigation funds from Spanish Rheumatology Foundation and Cruces Hospital Rheumatology Association; A-KT: Research support from Ardea Biosience\/Astra Zeneca, Berlin Chemie Menarini; Lecture fees from Berlin Chemie Menarini, Gruenenthal, Novartis; PR: fees from Ipsen, Menarini, Gr\u00fcnenthal, Savient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}